[1] S.M. Paul, D.S. Mytelka, C.T. Dunwiddie, C.C. Persinger, B.H. Munos, S.R. Lindborg, A.L. Schacht, How to improve R&D productivity: the pharmaceutical industry's grand challenge, Nat Rev Drug Discov., 9(3), 203–214 (2010)
[2] J.A. DiMasi, R.W. Hansen, H.G. Grabowski, The price of innovation: new estimates of drug development costs, J Health Econ., 22(2), 151–185 (2003).
[3] C.P. Adams, V.V. Brantner, Estimating the cost of new drug development: is it really 802 million dollars?, Health Aff (Millwood)., 25(2), 420–428 (2006).
[4] A.D. Hingorani, V. Kuan, C. Finan, F.A. Kruger, A. Gaulton, S. Chopade, R. Sofat, R.J. MacAllister, J.P. Overington, H. Hemingway, S. Denaxas, D. Prieto, J.P. Casas, Improving the odds of drug development success through human genomics: modelling study, Sci Rep., 9(1), 18911 (2019).
[5] D.F. McGinnity, M.G. Soars, R.A. Urbanowicz, R.J. Riley, Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance, Drug Metab Dispos., 32(11), 1247–1253 (2004).
[6] H. Suzuki, Y. Sugiyama, Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine, Eur J Pharm Sci., 12(1), 3–12 (2000).
[7] L.S. Kaminsky, Q.Y. Zhang, The small intestine as a xenobiotic-metabolizing organ, Drug Metab Dispos., 31(12), 1520–1525 (2003).
[8] J.H. Lin, Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics, Drug Metab Dispos., 26(12), 1202–1212 (1998).
[9] B.G. Lake, R.J. Price, A.M. Giddings, D.G. Walters, In vitro assays for induction of drug metabolism, Methods Mol Biol., 481, 47–58 (2009).
[10] E.F. Brandon, C.D. Raap, I. Meijerman, J.H. Beijnen, J.H.M. Schellens, An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons, Toxical. Appl. Pharmacol., 189, 233–246 (2003).
[11] H. Lennernäs, K. Palm, U. Fagerholm, P. Artursson, Comparison between active and passive drug transport in human intestinal epithelial (caco-2) cells in vitro and human jejunum in vivo, Int J Pharm., 127(1), 103–107 (1996).
[12] R. Hayeshi, C. Hilgendorf, P. Artursson, P. Augustijns, B. Brodin, P. Dehertogh, K. Fisher, L. Fossati, E. Hovenkamp, T. Korjamo, C. Masungi, N. Maubon, R. Mols, A. Müllertz, J. Mönkkönen, C. O'Driscoll, H.M. Oppers-Tiemissen, E.G. Ragnarsson, M. Rooseboom, A.L. Ungell, Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories, Eur J Pharm Sci., 35(5), 383– 396 (2008).
[13] D. Sun, H. Lennernas, L.S. Welage, J.L. Barnett, C.P. Landowski, D. Foster, D. Fleisher, K.D. Lee, G.L. Amidon, Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs, Pharm Res., 19(10), 1400–1416 (2002).
[14] K. Takahashi, S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, Cell, 126(4), 663–676 (2006).
[15] I.H. Park, R. Zhao, J.A. West, A. Yabuuchi, H. Huo, T.A. Ince, P.H. Lerou, M.W. Lensch, G.Q. Daley, Reprogramming of human somatic cells to pluripotency with defined factors, Nature, 451(7175), 141–146 (2008)..
[16] Y. Shi, H. Inoue, J.C. Wu, S. Yamanaka, Induced pluripotent stem cell technology: a decade of progress, Nat Rev Drug Discov., 16(2), 115–130 (2016).
[17] Y. Kondo, T. Iwao, K. Nakamura, T. Sasaki, S. Takahashi, N. Kamada, T. Matsubara, F.J. Gonzalez, H. Akutsu, Y. Miyagawa, H. Okita, N. Kiyokawa, M. Toyoda, A. Umezawa, K. Nagata, T. Matsunaga, S. Ohmori, An efficient method for differentiation of human induced pluripotent stem cells into hepatocyte-like cells retaining drug metabolizing activity, Drug Metab Pharmacokinet., 29(3), 237–243 (2014).
[18] H. Okumura, A. Nakanishi, T. Hashita, T. Iwao, T. Matsunaga, Effect of Celecoxib on Differentiation of human induced pluripotent stem cells into hepatocytes involves STAT5 activation, Drug Metab Dispos., 26, 1519–1527 (2018).
[19] K. Takayama, Y. Hagihara, Y. Toba, K. Sekiguchi, F. Sakurai, H. Mizuguchi, Enrichment of high-functioning human iPS cell-derived hepatocyte-like cells for pharmaceutical research, Biomaterials, 161, 24–32 (2018).
[20] N. Shiraki, Y. Shiraki, T. Tsuyama, F. Obata, M. Miura, G. Nagae, H. Aburatani, K. Kume, F. Endo, S. Kume, Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells, Cell Metab., 19(5), 780–794 (2014).
[21] T.K. Noah, B. Donahue, N.F. Shroyer, Intestinal development and differentiation, Exp Cell Res., 317, 2702–2710 (2011).
[22] A.A. Palakkan, J. Nanda, J.A. Ross, Human Induced Pluripotent Stem Cell-Derived Definitive Endoderm Bulk Culture and Hepatic Differentiation, Methods Mol. Biol., 1994, 41–53 (2019).
[23] T. Iwao, N. Kodama, Y. Kondo, T. Kabeya, K. Nakamura, T. Horikawa, T. Niwa, K. Kurose, T. Matsunaga, Generation of enterocyte-like cells with pharmacokinetic functions from human induced pluripotent stem cells using small-molecule compounds, Drug Metab Dispos., 43(4), 603–610 (2015).
[24] S S. Ogaki, N. Shiraki, K. Kume, S. Kume, Wnt and Notch signals guide embryonic stem cell differentiation into the intestinal lineages, Stem Cells, 31(6), 1086–1096 (2013).
[25] E.G. Giannini, C. Mansi, P. Dulbecco, V. Savarino, Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome, Nutrition, 22(3), 334–342 (2006).
[26] D.L. Seidner, B.A. Lashner, A. Brzezinski, P.L.C. Banks, J. Goldblum, C. Fiocchi, J. Katz, G.R. Lichtenstein, P.A. Anton, L.Y. Kam, K.A. Garleb, S.J. Demichele, An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: A randomized, controlled trial, Clin Gastroenterol Hepatol., 3(4), 358–369 (2005).
[27] J.A. Thomson, J. Itskovitz-Eldor, S.S. Shapiro, M.A. Waknitz, J.J. Swiergiel, V.S. V.S. Marshall, J.M. Jones, Embryonic stem cell lines derived from human blastocysts, Science, 282(5391), 1145–1147 (1998).
[28] M. Nakagawa, Y. Taniguchi, S. Senda, N. Takizawa, T. Ichisaka, K. Asano, A. Morizane, D. Doi, J. Takahashi, M. Nishizawa, Y. Yoshida, T. Toyoda, K. Osafune, K. Sekiguchi, S. Yamanaka, A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells, Sci Rep., 4, 3594 (2014).
[29] K. Osafune, L. Caron, M. Borowiak, R.J. Martinez, C.S. Fitz-Gerald, Y. Sato, C.A. Cowan, K.R. Chien, D.A. Melton, D.A. Melton, Marked differences in differentiation propensity among human embryonic stem cell lines, Nat. Biotechnol., 26, 313–315 (2008).
[30] A. Kubo, K. Shinozaki, J.M. Shannon, V. Kouskoff, M. Kennedy, S. Woo, H.J. Fehling, G. Keller, Development of definitive endoderm from embryonic stem cells in culture, Development, 131, 1651–1662 (2004).
[31] D. Sambo, J. Li, T. Brickler, S. Chetty, Transient treatment of human pluripotent stem cells with DMSO to promote differentiation. J. Vis. Exp., 149, 1–11 (2019).
[32] K.M. Loh, L.T. Ang, J. Zhang, V. Kumar, J. Ang, J.Q. Auyeong, K.L. Lee, S.H. Choo, C.Y. Lim, M. Nichane, J. Tan, M.S. Noghabi, L. Azzola, E.S. Ng, J. Durruthy-Durruthy, V. Sebastiano, L. Poellinger, A.G. Elefanty, E.G. Stanley, Q. Chen, S. Prabhakar, I.L. Weissman, B. Lim, Efficient endoderm induction from human pluripotent stem cells by logically directing signals controlling lineage bifurcations, Cell Stem Cell, 14(2), 237– 252 (2014).
[33] S. Ogaki, M. Morooka, K. Otera, S. Kume, A cost-effective system for differentiation of intestinal epithelium from human induced pluripotent stem cells, Sci Rep., 5, 17297 (2015).
[34] S. Chetty, F.W. Pagliuca, C. Honore, A. Kweudjeu, A. Rezania, D.A. Melton , A simple tool to improve pluripotent stem cell differentiation, Nat Methods., 10, 553–556 (2013).
[35] T. Kabeya, S. Mima, Y. Imakura, T. Miyashita, I. Ogura, T. Yamada, T. Yasujima, H. Yuasa, T. Iwao, T. Matsunaga, Pharmacokinetic functions of human induced pluripotent stem cell-derived small intestinal epithelial cells, Drug Metab Pharmacokinet., 35(4), 374–382 (2020).
[36] K.A. D'Amour, A.D. Agulnick, S. Eliazer, O.G. Kelly, E. Kroon, E.E. Baetge, Efficient differentiation of human embryonic stem cells to definitive endoderm, Nat Biotechnol., 23(12), 1534–1541 (2005)
[37] C. Bock, E. Kiskinis, G. Verstappen, H. Gu, G. Boulting, Z.D. Smith, M. Ziller, G.F. Croft, M.W. Amoroso, D.H. Oakley, A. Gnirke, K. Eggan, A. Meissner, Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines, Cell, 144, 439–452 (2011).
[38] N. Matoba, T. Yamashita, K. Takayama, F. Sakurai, H. Mizuguchi, Optimal human iPS cell culture method for efficient hepatic differentiation, Differentiation, 104, 13–21 (2018).
[39] K. Scheibner, M. Bakhti, A. Bastidas-Ponce, H. Lickert, Wnt signaling: implications in endoderm development and pancreas organogenesis, Curr Opin Cell Biol., 61, 48–55 (2019).
[40] S. Li, Q. Huang, J. Mao, Q. Li, FGF signaling mediates definitive endoderm formation by regulating epithelial-to-mesenchymal transition and cell proliferation, Int J Dev Biol., 64, 471–477 (2020).
[41] A.B. McLean, K.L. D'Amour, K.L. Jones, M. Krishnamoorthy, M.J. Kulik, D.M. Reynolds, A.M. Sheppard, H. Liu, Y. Xu, E.E. Baetge, S. Dalton, Activin a efficiently specifies definitive endoderm from human embryonic stem cells only when phosphatidylinositol 3-kinase signaling is suppressed, Stem Cells, 25, 29–38 (2007).
[42] X. Xu, V.L. Browning, J.S. Odorico, Activin, BMP and FGF pathways cooperate to promote endoderm and pancreatic lineage cell differentiation from human embryonic stem cells, Mech Dev., 128, 412–427 (2011).
[43] H. Komura, M. Iwaki, In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences, Drug Metab Rev., 43(4), 476–498 (2011).
[44] K. Yoshida, Y. Maeda K Fau - Sugiyama, Y. Sugiyama, Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms, Annu Rev Pharmacol Toxicol., 53, 581–612 (2013).
[45] M.C. Aldhous, A.N. Shmakov, J. Bode, S. Ghosh, Characterization of conditions for the primary culture of human small intestinal epithelial cells, Clin Exp Immunol.,125(1) 32–40 (2001).
[46] P. Chougule, G. Herlenius, N.M. Hernandez, P.B. Patil, B. Xu, S. Sumitran- Holgersson, Isolation and characterization of human primary enterocytes from small intestine using a novel method, Scand J Gastroenterol., 47(11), 1334–1343 (2012).
[47] T. Iwao, M. Toyota, Y. Miyagawa, H. Okita, N. Kiyokawa, H. Akutsu, A. Umezawa, K. Nagata, T. Matsunaga, Differentiation of human induced pluripotent stem cells into functional enterocyte-like cells using a simple method, Drug Metab Pharmacokinet., 29(1), 44–51 (2014).
[48] C. Cencetti, D. Bellini, A. Pavesio, D. Senigaglia, C. Passariello, A. Virga, P. Matricardi, Preparation and characterization of antimicrobial wound dressings based on silver, gellan, PVA and borax, Carbohydr Polym., 90(3), 1362–1370 (2012).
[49] Y. Gong, C. Wang, R.C. Lai, K. Su, F. Zhang, D. Wang, An improved injectable polysaccharide hydrogel: modified gellan gum for long-term cartilage regeneration in vitro, J Mater Chem., 19(14), 1968–1977 (2009).
[50] R. Goyal, S.K. Tripathi, S. Tyagi, K. Ravi Ram, K.M. Ansari, Y. Shukla, D. Kar Chowdhuri, P. Kumar, K.C. Gupta, Gellan gum blended PEI nanocomposites as gene delivery agents: evidences from in vitro and in vivo studies, Eur J Pharm Biopharm., 79(1), 3–14 (2011).
[51] N. Kodama, T. Iwao, T. Katano, K. Ohta, H. Yuasa, T. Matsunaga, Characteristic Analysis of Intestinal Transport in Enterocyte-Like Cells Differentiated from Human Induced Pluripotent Stem Cells, Drug Metab Dispos., 44(10), 1662–1667 (2016).
[52] H. Dowden, J. Munro, Trends in clinical success rates and therapeutic focus, Nat Rev Drug Discov., 18(7), 495–496 (2019).
[53] M. Puzan, S. Hosic, C. Ghio, A. Koppes, Enteric Nervous System Regulation of Intestinal Stem Cell Differentiation and Epithelial Monolayer Function, Sci Rep., 8(1), 6313 (2018).
[54] L.C. Delon, Z. Guo, A. Oszmiana, C.C. Chien, R. Gibson, C. Prestidge, B. Thierry, A systematic investigation of the effect of the fluid shear stress on Caco-2cells towards the optimization of epithelial organ-on-chip models, Biomaterials, 225, 119521 (2019).
[55] M.F. Paine, H.L. Hart, S.S. Ludington, R.L. Haining, A.E. Rettie, D.C. Zeldin, The human intestinal cytochrome P450 "pie", Drug Metab Dispos., 34(5), 880–886 (2006).
[56] H.Y. Chen, L. Pan, H.L. Yang, P. Xia, W.C. Yu, W.Q. Tang, Y.X. Zhang, S.F. Chen, Y.Z. Xue, L.X. Wang, Integrin alpha5beta1 suppresses rBMSCs anoikis and promotes nitric oxide production, Biomed Pharmacother., 99, 1–8 (2018).
[57] J. Alanko, A. Mai, G. Jacquemet, K. Schauer, R. Kaukonen, M. Saari, B. Goud, J. Ivaska, Integrin endosomal signalling suppresses anoikis, Nat Cell Biol., 17(11), 1412– 1421 (2015).
[58] F. d'Adda di Fagagna, S.H. Teo, S.P. Jackson, Functional links between telomeres and proteins of the DNA-damage response, Genes Dev., 18(15), 1781–1799 (2004).
[59] P.M. Warren, M.A. Pepperman, R.D. Montgomery, Age changes in small-intestinal mucosa, Lancet, 2(8094), 849–850 (1978).
[60] G.R. Corazza, M. Frazzoni, M.R. Gatto, G. Gasbarrini, Ageing and small-bowel mucosa: a morphometric study, Gerontology, 32(1), 60–65 (1986).
[61] W.T. Steegenga, N.J. de Wit, M.V. Boekschoten, N. Ijssennagger, C. Lute, S. Keshtkar, M.M. Bromhaar, E. Kampman, L.C. de Groot, M. Muller, Structural, functional and molecular analysis of the effects of aging in the small intestine and colon of C57BL/6J mice, BMC Med Genomics., 5, 38 (2012).
[62] J.P. Brown, W. Wei, J.M. Sedivy, Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts, Science, 277(5327), 831–834 (1997).
[63] A. Karimian, Y. Ahmadi, B. Yousefi, Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage, DNA Repair (Amst), 42, 63– 71 (2016).
[64] T. Natori, M. Fujiyoshi, M. Uchida, N. Abe, T. Kanaki, Y. Fukumoto, I. Ishii, Growth arrest of vascular smooth muscle cells in suspension culture using low-acyl gellan gum, In Vitro Cell Dev Biol Anim., 53(3), 191–198 (2017).